Vascular endothelial growth factor/semaphorin-3A ratio and SEMA3A expression in cutaneous malignant melanoma
- 1 October 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Melanoma Research
- Vol. 30 (5), 433-442
- https://doi.org/10.1097/CMR.0000000000000674
Abstract
Breslow thickness and Clark level are still important factors for cutaneous melanoma, but do not provide a precise prognosis in all cases. It is necessary to find new factors capable of a more accurate prediction of the tumor course. Angiogenesis is essential for tumor development and progression and is regulated by vascular endothelial growth factor A (VEGF-A) and semaphorins (SEMA), in particular, SEMA3A inhibits angiogenesis by affecting VEGF signaling. However, the prognostic role of angiogenetic factors remains unclear. To date, no information is available on SEMA3A in human melanoma. Microvessel density, immunohistochemical and mRNA VEGF and SEMA3A expression level in 60 thin (Breslow thickness <= 1.0 mm), 60 intermediate (1.1-4.0 mm) and 50 thick (>4.0 mm) primary human cutaneous melanomas were investigated and related to clinical/pathological parameters and disease-specific survival. No positive association between Breslow thickness, Clark level, metastasis presence and survival was identified; Clark level was poorly related to survival. VEGF and microvessel density were significantly higher in intermediate and thick melanomas and related to Breslow thickness and Clark level but not to metastasis status and survival. On the contrary, SEMA3A was significantly reduced in intermediate and thick melanomas and associated to metastasis and poor survival. VEGF/SEMA3A ratio was higher in the worst prognosis, resulting the most closely related factor with metastasis and survival. SEMA3A expression and VEGF/SEMA3A ratio turned out to be valuable prognostic biomarkers in patients affected by cutaneous melanoma, in particular with Breslow thickness >1 mm. SEMA3A might serve as a candidate tumor suppressor in cutaneous melanoma therapy.This publication has 34 references indexed in Scilit:
- Semaphorin 3A Suppresses Tumor Growth and Metastasis in Mice Melanoma ModelPLOS ONE, 2012
- The influence of neuropilin-1 silencing on semaphorin 3A and 3C activity in B16(F10) murine melanoma cellsNeoplasma, 2012
- Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomasWorld Journal of Clinical Oncology, 2012
- Class 3 semaphorins and their receptors in physiological and pathological angiogenesisBiochemical Society Transactions, 2011
- Basic and Therapeutic Aspects of AngiogenesisCell, 2011
- A Phase 2 Trial of Bevacizumab and High-dose Interferon Alpha 2B in Metastatic MelanomaJournal of Immunotherapy, 2011
- Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse modelsJCI Insight, 2009
- Successful Inhibition of Tumor Development by Specific Class-3 Semaphorins Is Associated with Expression of Appropriate Semaphorin Receptors by Tumor CellsPLOS ONE, 2008
- A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant MelanomaAnnals of Surgical Oncology, 2007
- Potential role of CCL27 and CCR10 expression in melanoma progression and immune escapeEuropean Journal of Cancer, 2006